Dutch Medical Firm Secures Millions to Advance Living Blood Vessel Implants
Eindhoven, Thursday, 6 August 2026.
Dutch medtech pioneer Xeltis secured €20.5 million to commercialize a groundbreaking synthetic implant that gradually transforms into the patient’s own living, functional blood vessels.
A Breakthrough in Healthtech and Restorative Medicine
This pioneering innovation falls squarely under the category of healthtech and restorative medicine, representing a paradigm shift in how cardiovascular and vascular access complications are treated [3][5]. Developed by Xeltis, a medical technology scale-up based in Eindhoven, the Netherlands, the technology is led by Chief Executive Officer Eliane Schutte [4][5]. The company’s primary focus is addressing the severe limitations of traditional hemodialysis vascular access and cardiovascular replacements, which historically have relied on permanent synthetic or biological grafts that are prone to failure, infections, and rejection [1][5]. By offering a bioabsorbable alternative, Xeltis seeks to drastically reduce clinical complications and improve patient outcomes globally [1][3].
How the Restorex Platform Works
At the core of this innovation is Xeltis’ proprietary Restorex platform [5]. The technology functions by utilizing a synthetic, polymer-based implant that acts as a temporary scaffold [1][5]. Once implanted into the patient, the body’s natural healing process is triggered, allowing the patient’s own cells to populate the scaffold and gradually reconstruct a living, functional blood vessel [1][5]. Over time, the synthetic polymer implant is safely and naturally absorbed by the body, leaving behind nothing but the patient’s own newly formed living tissue [1][5]. This process represents a major leap forward from traditional vascular implants, which remain permanent foreign objects inside the body [1][2].
Clinical Benefits and European Rollout
The immediate application of this technology is the aXess vascular access device, designed specifically for kidney patients requiring hemodialysis [3][4]. Hemodialysis requires reliable and repeated access to the bloodstream to cleanse the blood when kidneys fail, and the aXess device provides a highly durable and biocompatible pathway for this therapy [4]. Xeltis has already achieved significant milestones with this device, having secured CE Mark approval and initiated its commercial launch in Europe [3][5]. Prior to August 2026, the company successfully treated its first commercial patient using the aXess implant in Germany, marking an important step toward widespread clinical adoption [1][3].
Securing Capital for Global Expansion
To accelerate its global growth, Xeltis announced an additional €20.5 million in funding on July 28, 2026 [2][5]. This funding round was led by new investor Horizon 3 Healthcare, with participation from the European Innovation Council (EIC) Fund, Invest-NL, VI Partners, EQT Life Sciences, and DaVita [1][2]. Combined with the €50 million secured in 2025 from the European Investment Bank (EIB) and existing shareholders, the company’s total funding has reached 70.5 million [3][5]. According to Chief Investment Officer of Horizon 3 Healthcare, Matt McNamara, the clinical data generated by Xeltis to date is highly compelling and highlights the potential of aXess to transform the hemodialysis access landscape [1][2].
The Path Toward FDA Approval
The newly secured capital will be strategically deployed to advance Xeltis’ clinical and regulatory pathways in the United States, where its ongoing US pivotal trial for the aXess device has already surpassed 50% patient enrollment [3]. The company is actively preparing for its submission to the US Food and Drug Administration (FDA) and laying the groundwork for its US market commercialization [3][4]. Furthermore, the proceeds will support the upscaling of manufacturing capabilities and the clinical advancement of its other pipeline programs, including the Xeltis coronary artery bypass graft (XABG) program and the Xeltis peripheral artery disease (XPAD) bypass conduit clinical program [3][5].